241 related articles for article (PubMed ID: 33781343)
1. Characterization of the mechanism of action of lanraplenib, a novel spleen tyrosine kinase inhibitor, in models of lupus nephritis.
Pohlmeyer CW; Shang C; Han P; Cui ZH; Jones RM; Clarke AS; Murray BP; Lopez DA; Newstrom DW; Inzunza MD; Matzkies FG; Currie KS; Di Paolo JA
BMC Rheumatol; 2021 Mar; 5(1):15. PubMed ID: 33781343
[TBL] [Abstract][Full Text] [Related]
2. BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis.
Chalmers SA; Glynn E; Garcia SJ; Panzenbeck M; Pelletier J; Dimock J; Seccareccia E; Bosanac T; Khalil S; Harcken C; Webb D; Nabozny G; Fine JS; Souza D; Klein E; Herlitz L; Ramanujam M; Putterman C
Clin Immunol; 2018 Dec; 197():205-218. PubMed ID: 30339790
[TBL] [Abstract][Full Text] [Related]
3. HM71224, a selective Bruton's tyrosine kinase inhibitor, attenuates the development of murine lupus.
Kim YY; Park KT; Jang SY; Lee KH; Byun JY; Suh KH; Lee YM; Kim YH; Hwang KW
Arthritis Res Ther; 2017 Sep; 19(1):211. PubMed ID: 28950886
[TBL] [Abstract][Full Text] [Related]
4. A novel selective spleen tyrosine kinase inhibitor SKI-O-703 (cevidoplenib) ameliorates lupus nephritis and serum-induced arthritis in murine models.
Cho S; Jang E; Yoon T; Hwang H; Youn J
Clin Exp Immunol; 2023 Mar; 211(1):31-45. PubMed ID: 36346114
[TBL] [Abstract][Full Text] [Related]
5. Raloxifene modulates estrogen-mediated B cell autoreactivity in NZB/W F1 mice.
Zhang Y; Saha S; Rosenfeld G; Gonzalez J; Pepeljugoski KP; Peeva E
J Rheumatol; 2010 Aug; 37(8):1646-57. PubMed ID: 20551107
[TBL] [Abstract][Full Text] [Related]
6. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).
Werwitzke S; Trick D; Sondermann P; Kamino K; Schlegelberger B; Kniesch K; Tiede A; Jacob U; Schmidt RE; Witte T
Ann Rheum Dis; 2008 Feb; 67(2):154-61. PubMed ID: 17557887
[TBL] [Abstract][Full Text] [Related]
7. The Systemic Activation of Programmed Death 1-PD-L1 Axis Protects Systemic Lupus Erythematosus Model from Nephritis.
Liao W; Zheng H; Wu S; Zhang Y; Wang W; Zhang Z; Zhou C; Wu H; Min J
Am J Nephrol; 2017; 46(5):371-379. PubMed ID: 29069649
[TBL] [Abstract][Full Text] [Related]
8. Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFN
Katewa A; Wang Y; Hackney JA; Huang T; Suto E; Ramamoorthi N; Austin CD; Bremer M; Chen JZ; Crawford JJ; Currie KS; Blomgren P; DeVoss J; DiPaolo JA; Hau J; Johnson A; Lesch J; DeForge LE; Lin Z; Liimatta M; Lubach JW; McVay S; Modrusan Z; Nguyen A; Poon C; Wang J; Liu L; Lee WP; Wong H; Young WB; Townsend MJ; Reif K
JCI Insight; 2017 Apr; 2(7):e90111. PubMed ID: 28405610
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of G Protein βγ Subunit Signaling Abrogates Nephritis in Lupus-Prone Mice.
Rangel-Moreno J; To JY; Owen T; Goldman BI; Smrcka AV; Anolik JH
Arthritis Rheumatol; 2016 Sep; 68(9):2244-56. PubMed ID: 26990948
[TBL] [Abstract][Full Text] [Related]
10. HSPB5 suppresses renal inflammation and protects lupus-prone NZB/W F1 mice from severe renal damage.
Knapp J; Braunstein M; Berg SIT; Shirriff C
Arthritis Res Ther; 2022 Dec; 24(1):267. PubMed ID: 36510250
[TBL] [Abstract][Full Text] [Related]
11. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus.
Bahjat FR; Pine PR; Reitsma A; Cassafer G; Baluom M; Grillo S; Chang B; Zhao FF; Payan DG; Grossbard EB; Daikh DI
Arthritis Rheum; 2008 May; 58(5):1433-44. PubMed ID: 18438845
[TBL] [Abstract][Full Text] [Related]
12. Selective Histone Deacetylase 6 Inhibition Normalizes B Cell Activation and Germinal Center Formation in a Model of Systemic Lupus Erythematosus.
Ren J; Catalina MD; Eden K; Liao X; Read KA; Luo X; McMillan RP; Hulver MW; Jarpe M; Bachali P; Grammer AC; Lipsky PE; Reilly CM
Front Immunol; 2019; 10():2512. PubMed ID: 31708928
[TBL] [Abstract][Full Text] [Related]
13. Selective HDAC6 inhibition decreases early stage of lupus nephritis by down-regulating both innate and adaptive immune responses.
Ren J; Liao X; Vieson MD; Chen M; Scott R; Kazmierczak J; Luo XM; Reilly CM
Clin Exp Immunol; 2018 Jan; 191(1):19-31. PubMed ID: 28876451
[TBL] [Abstract][Full Text] [Related]
14. The Ox40/Ox40 Ligand Pathway Promotes Pathogenic Th Cell Responses, Plasmablast Accumulation, and Lupus Nephritis in NZB/W F1 Mice.
Sitrin J; Suto E; Wuster A; Eastham-Anderson J; Kim JM; Austin CD; Lee WP; Behrens TW
J Immunol; 2017 Aug; 199(4):1238-1249. PubMed ID: 28696253
[TBL] [Abstract][Full Text] [Related]
15. B1-cell-produced anti-phosphatidylserine antibodies contribute to lupus nephritis development via TLR-mediated Syk activation.
Ma K; Du W; Wang S; Xiao F; Li J; Tian J; Xing Y; Kong X; Rui K; Qin R; Zhu X; Wang J; Luo C; Wu H; Zhang Y; Wen C; He L; Liu D; Zou H; Lu Q; Wu L; Lu L
Cell Mol Immunol; 2023 Aug; 20(8):881-894. PubMed ID: 37291237
[TBL] [Abstract][Full Text] [Related]
16. Suppression of renal disease and mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus (SLE) by chenodeoxycholic acid.
Suwannaroj S; Lagoo A; McMurray RW
Lupus; 2001; 10(8):562-7. PubMed ID: 11530998
[TBL] [Abstract][Full Text] [Related]
17. Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy.
Baker M; Chaichian Y; Genovese M; Derebail V; Rao P; Chatham W; Bubb M; Lim S; Hajian H; Gurtovaya O; Patel U; Tumlin J
RMD Open; 2020 Dec; 6(3):. PubMed ID: 33380521
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulatory effects of H.P. Acthar Gel on B cell development in the NZB/W F1 mouse model of systemic lupus erythematosus.
Decker DA; Grant C; Oh L; Becker PM; Young D; Jordan S
Lupus; 2014 Jul; 23(8):802-12. PubMed ID: 24759631
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular changes in the NZB/W F1 mouse model of lupus nephritis.
Böhme R; Daniel C; Ferrazzi F; Angeloni M; Ekici AB; Winkler TH; Hilgers KF; Wellmann U; Voll RE; Amann K
Front Cardiovasc Med; 2023; 10():1182193. PubMed ID: 37554366
[TBL] [Abstract][Full Text] [Related]
20. Increased frequency of a unique spleen tyrosine kinase bright memory B cell population in systemic lupus erythematosus.
Fleischer SJ; Giesecke C; Mei HE; Lipsky PE; Daridon C; Dörner T
Arthritis Rheumatol; 2014 Dec; 66(12):3424-35. PubMed ID: 25156507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
